87 related articles for article (PubMed ID: 8797869)
1. Detection of auto-antibodies against L-myc oncogene products in sera from lung cancer patients.
Yamamoto A; Shimizu E; Ogura T; Sone S
Int J Cancer; 1996 Aug; 69(4):283-9. PubMed ID: 8797869
[TBL] [Abstract][Full Text] [Related]
2. Infrequent presence of anti-c-Myc antibodies and absence of c-Myc oncoprotein in sera from lung cancer patients.
Yamamoto A; Shimizu E; Takeuchi E; Houchi H; Doi H; Bando H; Ogura T; Sone S
Oncology; 1999; 56(2):129-33. PubMed ID: 9949299
[TBL] [Abstract][Full Text] [Related]
3. L-Myc overexpression and detection of auto-antibodies against L-Myc in both the serum and pleural effusion from a patient with non-small cell lung cancer.
Yamamoto A; Shimizu E; Sumitomo K; Shinohara A; Namikawa O; Uehara H; Sone S
Intern Med; 1997 Oct; 36(10):724-7. PubMed ID: 9372336
[TBL] [Abstract][Full Text] [Related]
4. Presence of antibodies against retinoblastoma tumor suppressor protein in patients with lung cancer.
Matsumoto S; Teramoto H; Nakamoto M; Igishi T; Kawasaki Y; Shimizu E
Int J Oncol; 2001 Nov; 19(5):1035-9. PubMed ID: 11605006
[TBL] [Abstract][Full Text] [Related]
5. Humoral immune response to p16, a cyclin-dependent kinase inhibitor in human malignancies.
Looi K; Megliorino R; Shi FD; Peng XX; Chen Y; Zhang JY
Oncol Rep; 2006 Nov; 16(5):1105-10. PubMed ID: 17016600
[TBL] [Abstract][Full Text] [Related]
6. Analysis of antibodies to p16INK4A tumor suppressor gene products in lung cancer patients.
Namikawa O; Shimizu E; Sumitomo K; Sone S
Int J Oncol; 1999 Apr; 14(4):681-5. PubMed ID: 10087314
[TBL] [Abstract][Full Text] [Related]
7. Development of antibodies against p53 in lung cancer patients appears to be dependent on the type of p53 mutation.
Winter SF; Minna JD; Johnson BE; Takahashi T; Gazdar AF; Carbone DP
Cancer Res; 1992 Aug; 52(15):4168-74. PubMed ID: 1322237
[TBL] [Abstract][Full Text] [Related]
8. Circulating antibodies to p40(AIS) in the sera of respiratory tract cancer patients.
Yamaguchi K; Patturajan M; Trink B; Usadel H; Koch W; Jen J; Sidransky D
Int J Cancer; 2000 Nov; 89(6):524-8. PubMed ID: 11102898
[TBL] [Abstract][Full Text] [Related]
9. A novel capture-ELISA for detection of anti-neutrophil cytoplasmic antibodies (ANCA) based on c-myc peptide recognition in carboxy-terminally tagged recombinant neutrophil serine proteases.
Lee AS; Finkielman JD; Peikert T; Hummel AM; Viss MA; Specks U
J Immunol Methods; 2005 Dec; 307(1-2):62-72. PubMed ID: 16242707
[TBL] [Abstract][Full Text] [Related]
10. A polyclonal antibody against synthetic peptide conserved in N-Myc protein reacts with water-soluble recombinant N-Myc protein.
Yang HW; Hemmi H; Ikeda H; Kato K; Tsuchida Y
Oncol Rep; 1999; 6(1):107-11. PubMed ID: 9864411
[TBL] [Abstract][Full Text] [Related]
11. Autoantibodies to c-myc protein: elevated levels in patients with African Burkitt's lymphoma and normal Ghanians.
LaFond RE; Eaton RB; Watt RA; Villee CA; Actor JK; Schur PH
Autoimmunity; 1992; 13(3):215-24. PubMed ID: 1472633
[TBL] [Abstract][Full Text] [Related]
12. Detection of the anti-Hu antibody in the serum of patients with small cell lung cancer--a quantitative western blot analysis.
Dalmau J; Furneaux HM; Gralla RJ; Kris MG; Posner JB
Ann Neurol; 1990 May; 27(5):544-52. PubMed ID: 2163235
[TBL] [Abstract][Full Text] [Related]
13. Autoantibodies against the Hel-N1 RNA-binding protein among patients with lung carcinoma: an association with type I anti-neuronal nuclear antibodies.
Dropcho EJ; King PH
Ann Neurol; 1994 Aug; 36(2):200-5. PubMed ID: 8053656
[TBL] [Abstract][Full Text] [Related]
14. Value of glutathione S-transferase pi and the oncogene products c-Jun, c-Fos, c-H-Ras, and c-Myc as a prognostic indicator in endometrial carcinomas.
Yokoyama Y; Sagara M; Sato S; Saito Y
Gynecol Oncol; 1998 Mar; 68(3):280-7. PubMed ID: 9570981
[TBL] [Abstract][Full Text] [Related]
15. Comparison of human sera reactivities in immunoblots with recombinant human herpesvirus (HHV)-8 proteins associated with the latent (ORF73) and lytic (ORFs 65, K8.1A, and K8.1B) replicative cycles and in immunofluorescence assays with HHV-8-infected BCBL-1 cells.
Zhu L; Wang R; Sweat A; Goldstein E; Horvat R; Chandran B
Virology; 1999 Apr; 256(2):381-92. PubMed ID: 10191203
[TBL] [Abstract][Full Text] [Related]
16. Recombinant plasmid expressing the entire coding region of the Bmyc putative protein.
Steinitz M; Ingvarsson S; Asker C; Sümegi J; Klein G
J Clin Lab Immunol; 1990 Jun; 32(2):49-54. PubMed ID: 1967038
[TBL] [Abstract][Full Text] [Related]
17. Expression of ras p21 and myc p62 oncoproteins in small cell and non small cell carcinoma of the lung.
Spandidos DA; Zakinthinos S; Petraki C; Sotsiou F; Yiagnisis M; Dimopoulos AM; Roussos C; Field JK
Anticancer Res; 1990; 10(5A):1105-14. PubMed ID: 2173469
[TBL] [Abstract][Full Text] [Related]
18. Detection of autoantibodies to livin and survivin in Sera from lung cancer patients.
Yagihashi A; Asanuma K; Kobayashi D; Tsuji N; Shijubo Y; Abe S; Hirohashi Y; Torigoe T; Sato N; Watanabe N
Lung Cancer; 2005 May; 48(2):217-21. PubMed ID: 15829321
[TBL] [Abstract][Full Text] [Related]
19. Autoimmune response to anti-apoptotic protein survivin and its association with antibodies to p53 and c-myc in cancer detection.
Megliorino R; Shi FD; Peng XX; Wang X; Chan EK; Tan EM; Zhang JY
Cancer Detect Prev; 2005; 29(3):241-8. PubMed ID: 15896923
[TBL] [Abstract][Full Text] [Related]
20. p53 protein, EGF receptor, and anti-p53 antibodies in serum from patients with occupationally derived lung cancer.
Schneider J; Presek P; Braun A; Bauer P; Konietzko N; Wiesner B; Woitowitz HJ
Br J Cancer; 1999 Aug; 80(12):1987-94. PubMed ID: 10471051
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
